Active Ingredient(s): Pasireotide Diaspartate
FDA Approved: * December 14, 2012
Pharm Company: * NOVARTIS PHARMS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Signifor Overview

Pasireotide (SOM230, trade name Signifor[2]) is an orphan drug approved in the United States[3] and Europe[4] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Pasireotide was approved for Cush...

Read more Signifor Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Signifor Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pasireotide Diaspartate
  • For Suspension: 10mg/vial, 20mg/vial, 30mg/vial, 40mg/vial, 60mg/vial
  • Injection: 0.3mg/1ml, 0.6mg/1ml, 0.9mg/1ml
  • Powder: 20mg/vial, 40mg/vial, 60mg/vial
  • Solution: 0.3mg/ml (0.3mg/ml), 0.6mg/ml (0.6mg/ml), 0.9mg/ml (0.9mg/ml)
  • Suspension: 20mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Signifor: (3 results)

Sorted by National Drug Code
  • 0078-0633 Signifor .3 mg/ml Subcutaneous Injection by Novartis Pharmaceuticals Corporation
  • 0078-0634 Signifor .6 mg/ml Subcutaneous Injection by Novartis Pharmaceuticals Corporation
  • 0078-0635 Signifor .9 mg/ml Subcutaneous Injection by Novartis Pharmaceuticals Corporation

Other drugs which contain Pasireotide Diaspartate or a similar ingredient: (2 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 August 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA